| Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells X Zhu, M Badawi, S Pomeroy, DS Sutaria, Z Xie, A Baek, J Jiang, ... Journal of extracellular vesicles 6 (1), 1324730, 2017 | 495 | 2017 |
| Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma VA Pullarkat, NJ Lacayo, E Jabbour, JE Rubnitz, A Bajel, TW Laetsch, ... Cancer discovery 11 (6), 1440-1453, 2021 | 216 | 2021 |
| Achieving the promise of therapeutic extracellular vesicles: the devil is in details of therapeutic loading DS Sutaria, M Badawi, MA Phelps, TD Schmittgen Pharmaceutical research 34, 1053-1066, 2017 | 132 | 2017 |
| Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery DS Sutaria, J Jiang, OA Elgamal, SM Pomeroy, M Badawi, X Zhu, ... Journal of extracellular vesicles 6 (1), 1333882, 2017 | 85 | 2017 |
| Antisense oligonucleotides: absorption, distribution, metabolism, and excretion M Shadid, M Badawi, A Abulrob Expert opinion on drug metabolism & toxicology 17 (11), 1281-1292, 2021 | 76 | 2021 |
| miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway J Kim, J Jiang, M Badawi, TD Schmittgen Biochemical and biophysical research communications 487 (3), 709-715, 2017 | 59 | 2017 |
| Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma J Jiang, ACP Azevedo-Pouly, RS Redis, EJ Lee, Y Gusev, D Allard, ... Oncotarget 7 (33), 53165, 2016 | 44 | 2016 |
| CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128 M Badawi, J Kim, A Dauki, D Sutaria, T Motiwala, R Reyes, N Wani, ... Oncotarget 9 (40), 26032, 2018 | 39 | 2018 |
| Approaches to handling missing or “problematic” pharmacology data: Pharmacokinetics DJ Irby, ME Ibrahim, AM Dauki, MA Badawi, SM Illamola, M Chen, ... CPT: pharmacometrics & systems pharmacology 10 (4), 291-308, 2021 | 33 | 2021 |
| Anti-invasion and anti-migration effects of miR-199a-3p in hepatocellular carcinoma are due in part to targeting CD151 JH Kim, M Badawi, JK Park, J Jiang, X Mo, LR Roberts, TD Schmittgen International journal of oncology 49 (5), 2037-2045, 2016 | 30 | 2016 |
| A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer S Sardesai, M Badawi, E Mrozek, E Morgan, M Phelps, J Stephens, L Wei, ... Investigational new drugs 38, 1400-1410, 2020 | 26 | 2020 |
| Pharmacokinetic‐Pharmacodynamic model of neutropenia in patients with myeloma receiving high‐dose Melphalan for autologous stem cell transplant YK Cho, DJ Irby, J Li, DW Sborov, DR Mould, M Badawi, A Dauki, ... CPT: Pharmacometrics & Systems Pharmacology 7 (11), 748-758, 2018 | 14 | 2018 |
| Loss of RE-1 silencing transcription factor accelerates exocrine damage from pancreatic injury JK Bray, OA Elgamal, J Jiang, LS Wright, DS Sutaria, M Badawi, ... Cell Death & Disease 11 (2), 138, 2020 | 13 | 2020 |
| Venetoclax Crosses the blood brain barrier: A pharmacokinetic analysis of the cerebrospinal fluid in pediatric leukemia patients AH Salem, MA Badawi, AE Place, TL Palenski, R Arrendale, SY Kim, ... Blood 136, 30-31, 2020 | 10 | 2020 |
| Venetoclax penetrates the blood brain barrier: a pharmacokinetic analysis in pediatric leukemia patients M Badawi, R Menon, AE Place, T Palenski, G Sunkersett, R Arrendale, ... Journal of Cancer 14 (7), 1151, 2023 | 8 | 2023 |
| Exposure–response or clearance–response relationship in immune checkpoint therapy?—A comment on ‘correlation between nivolumab exposure and treatment outcomes in non-small … M Badawi, CC Coss, MA Phelps European Journal of Cancer 114, 25-26, 2019 | 6 | 2019 |
| Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery. J Extracell Vesicles. 2017; 6: 1333882 DS Sutaria, J Jiang, OA Elgamal, SM Pomeroy, M Badawi, X Zhu, ... | 6 | |
| Bioavailability evaluation of venetoclax lower-strength tablets and oral powder formulations to establish interchangeability with the 100 mg tablet M Badawi, X Chen, P Marroum, AA Suleiman, S Mensing, ... Clinical Drug Investigation 42 (8), 657-668, 2022 | 5 | 2022 |
| Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11 (6 … VA Pullarkat, NJ Lacayo, E Jabbour, JE Rubnitz, A Bajel, TW Laetsch, ... | 5 | 2021 |
| Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia B Bhatnagar, Q Zhao, AS Mims, S Vasu, GK Behbehani, K Larkin, ... Leukemia & Lymphoma 64 (13), 2091-2100, 2023 | 4 | 2023 |
